Gene Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
Entrez Id: 7157
Gene Symbol: TP53
TP53
0.030 GeneticVariation disease BEFREE Genetic examination revealed mutations in EGFR and p53 that were of the same type as the lung tumor, leading to the final diagnosis of the femoral mass as a sarcomatous transformation of metastatic lung adenocarcinoma. 26045851 2015
Entrez Id: 3845
Gene Symbol: KRAS
KRAS
0.030 GeneticVariation disease BEFREE In this study, we have investigated EGFR and KRAS mutations in metastatic lung adenocarcinoma. 21497370 2011
Entrez Id: 673
Gene Symbol: BRAF
BRAF
0.020 GeneticVariation disease BEFREE Here, we report the case of a patient with metastatic lung adenocarcinoma with BRAF G469L mutation refractory to vemurafenib. 24035431 2013
Entrez Id: 673
Gene Symbol: BRAF
BRAF
0.020 GeneticVariation disease BEFREE In this report, we describe the case of a 71-year-old man who developed classic GA lesions while being treated with vemurafenib monotherapy for nonmelanoma cancer, specifically metastatic lung adenocarcinoma positive for BRAF V600 mutation.<p><em>J Drugs Dermatol.2017;16(10):1050-1052.</em></p>. 29036262 2017
Entrez Id: 5979
Gene Symbol: RET
RET
0.020 GeneticVariation disease BEFREE Resistance to vandetanib, a type I RET kinase inhibitor, developed in a patient with metastatic lung adenocarcinoma harboring a CCDC6-RET fusion that initially exhibited a response to treatment. 29434222 2018
Entrez Id: 8030
Gene Symbol: CCDC6
CCDC6
0.020 GeneticVariation disease BEFREE Resistance to vandetanib, a type I RET kinase inhibitor, developed in a patient with metastatic lung adenocarcinoma harboring a CCDC6-RET fusion that initially exhibited a response to treatment. 29434222 2018
Entrez Id: 29126
Gene Symbol: CD274
CD274
0.010 GeneticVariation disease BEFREE We report a patient with brain metastatic lung adenocarcinoma in whom fatal myocarditis developed after sequential use of PD-1 and PD-L1 inhibitors. 31022941 2019
Entrez Id: 51755
Gene Symbol: CDK12
CDK12
0.010 GeneticVariation disease BEFREE Quantitative Mass Spectrometry to Interrogate Proteomic Heterogeneity in Metastatic Lung Adenocarcinoma and Validate a Novel Somatic Mutation CDK12-G879V. 30617155 2019
Entrez Id: 972
Gene Symbol: CD74
CD74
0.010 GeneticVariation disease BEFREE Resistance to crizotinib developed in a patient with metastatic lung adenocarcinoma harboring a CD74-ROS1 rearrangement who had initially shown a dramatic response to treatment. 23724914 2013
Entrez Id: 1956
Gene Symbol: EGFR
EGFR
0.100 Biomarker disease BEFREE Successful pregnancy with epidermal growth factor receptor tyrosine kinase inhibitor treatment of metastatic lung adenocarcinoma presenting with respiratory failure. 21920622 2011
Entrez Id: 1956
Gene Symbol: EGFR
EGFR
0.100 Biomarker disease BEFREE Combined, these findings define a novel transcriptional network regulating oncogenic EGFR signaling and identify a class of FDA-approved drugs as capable of restoring chemosensitivity to anti-EGFR-based therapy for the treatment of metastatic lung adenocarcinoma. 22653055 2012
Entrez Id: 238
Gene Symbol: ALK
ALK
0.050 Biomarker disease BEFREE Presence of anaplastic lymphoma kinase (ALK) rearrangement is an indication for crizotinib in the treatment of patients with advanced or metastatic lung adenocarcinoma. 28118634 2017
Entrez Id: 238
Gene Symbol: ALK
ALK
0.050 Biomarker disease BEFREE A 45-year-old Korean female with ALK-rearranged metastatic lung adenocarcinoma underwent ceritinib treatment and exhibited a partial response, until she developed organizing pneumonia resembling disease progression. 30075548 2018
Entrez Id: 238
Gene Symbol: ALK
ALK
0.050 Biomarker disease BEFREE Effectiveness of crizotinib in a patient with ALK IHC-positive/FISH-negative metastatic lung adenocarcinoma. 27393517 2016
Entrez Id: 238
Gene Symbol: ALK
ALK
0.050 Biomarker disease BEFREE We describe a case of lichenoid drug eruption (LDE) that appeared 4 weeks after initiation of treatment with crizotinib in a 61-year-old man with ALK-positive metastatic lung adenocarcinoma. 30657798 2018
Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
0.040 Biomarker disease BEFREE Here, we sought to characterize tumor proteome and phosphoproteome changes by longitudinal, prospective collection of tumor tissue from an exceptional responder lung adenocarcinoma patient who survived with metastatic lung adenocarcinoma for over seven years while undergoing HER2-directed therapy in combination with chemotherapy. 30617155 2019
Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
0.040 Biomarker disease BEFREE EGFR, KRAS, BRAF and HER2 testing in metastatic lung adenocarcinoma: Value of testing on samples with poor specimen adequacy and analysis of discrepancies. 29175303 2017
Entrez Id: 8030
Gene Symbol: CCDC6
CCDC6
0.020 Biomarker disease BEFREE Multiplex reverse transcription-polymerase chain reaction (RT-PCR) was used to detect KIF5B-RET and CCDC6-RET fusions from specimens of malignant pleural effusion (MPE) in patients with metastatic lung adenocarcinoma. 25773866 2015
Entrez Id: 5979
Gene Symbol: RET
RET
0.020 Biomarker disease BEFREE Multiplex reverse transcription-polymerase chain reaction (RT-PCR) was used to detect KIF5B-RET and CCDC6-RET fusions from specimens of malignant pleural effusion (MPE) in patients with metastatic lung adenocarcinoma. 25773866 2015
Entrez Id: 59
Gene Symbol: ACTA2
ACTA2
0.010 Biomarker disease BEFREE Therefore, ACTA2 could be a promising prognostic biomarker and/or therapeutic target for metastatic lung adenocarcinoma. 23995859 2013
Entrez Id: 6098
Gene Symbol: ROS1
ROS1
0.010 Biomarker disease BEFREE We evaluated the diagnostic accuracy and interpathologist agreement of two anti-ROS1 IHC clones, SP384 (Ventana, Tucson, Arizona) and D4D6 (Cell Signaling, Danvers, Massachusetts), in a training cohort of 51 positive ROS1 FISH LUAD cases, and then in a large validation cohort of 714 consecutive cases of LUAD from six routine molecular pathology platforms. 30999109 2019
Entrez Id: 94025
Gene Symbol: MUC16
MUC16
0.010 Biomarker disease BEFREE To examine the serum levels of carcinoembryonic antigen (CEA), cytokeratin-19 fragments (CYFRA21-1), neuron-specific enolase (NSE), carbohydrate antigen (CA) 19-9, CA125, tissue polypeptide antigen (TPA), tissue polypeptide specific antigen (TPS), and lactate dehydrogenase (LDH) to predict de novo metastatic lung adenocarcinoma. 31356196 2019
Entrez Id: 3880
Gene Symbol: KRT19
KRT19
0.010 Biomarker disease BEFREE To examine the serum levels of carcinoembryonic antigen (CEA), cytokeratin-19 fragments (CYFRA21-1), neuron-specific enolase (NSE), carbohydrate antigen (CA) 19-9, CA125, tissue polypeptide antigen (TPA), tissue polypeptide specific antigen (TPS), and lactate dehydrogenase (LDH) to predict de novo metastatic lung adenocarcinoma. 31356196 2019
Entrez Id: 1499
Gene Symbol: CTNNB1
CTNNB1
0.010 Biomarker disease BEFREE Ubiquitin-specific protease 4 controls metastatic potential through β-catenin stabilization in brain metastatic lung adenocarcinoma. 26883469 2016
Entrez Id: 2150
Gene Symbol: F2RL1
F2RL1
0.010 Biomarker disease BEFREE Our finding also suggests that PAR2 might serve as a therapeutic target for metastatic lung adenocarcinoma and a potential biomarker for predicting the prognosis of lung adenocarcinoma. 30321617 2019